Investor Presentaiton
Multiple Strategies to Strengthen Portfolio and Enhance Value
for Our Clients and Shareholders
| | || | _
Disciplined M&A
Strategic Partnerships
Venture Capital
Relationships
M&A remains top, long-term priority for
disciplined capital deployment and
enhances growth strategy
Invested >$4.5B in >25 acquisitions
since 2012
Focused on enhancing breadth of
scientific capabilities, expanding global
scale, and maintaining leadership in
advanced and emerging therapies
Partnerships and licensing
arrangements add innovative capabilities
and cutting-edge technologies with
limited upfront risk
-20 active partnerships currently
with >$100M invested to date(1)
•
Highlights include:
Distributed Bio (acquired) - antibody discovery
SAMDI Tech (acquired) - label-free high-
throughput screening (HTS)
Cypre 3D tumor modeling
Wheeler Bio - Antibody manufacturing
Vernal Bio - mRNA manufacturing/LNP design
Innovative strategy to establish CRL as
a preferred partner to a large group of
emerging, VC-backed biotech
companies and create value
~10% of annual revenue comes from
VC-backed companies (2)
Slightly below 30% average annual
return on our VC relationships
(investments and revenue)(3)
(1)
Charles River Laboratories (CRL)
(2)
(3)
Amount invested in strategic partnerships excludes purchase price to acquire Distributed Bio.
VC revenue includes VC firms with which we have invested, those with which we have a strategic relationship, and other revenue from VC portfolio companies with which we have no formal relationship.
Return calculation as of FY 2022 includes VC investment gains and operating cash flow from revenue generated from VC funds in which we have invested (both net of tax). It does not include revenue generated from VC funds in which we have not invested.
20View entire presentation